Chenoa Sankar

Chenoa Sankar

Auto-generated profile, based on publicly available information

Chenoa Sankar

Centre for Vaccines & Immunology, National Institute for Communicable Diseases, A Division of the National Health Laboratory Service, Johannesburg, South Africa

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Vaccine
Verified
Journal Article
Open access
CSChenoa Sankar
Chenoa Sankar
JMJohanna C. Meyer
Johanna C. Meyer
MSMarione Schönfeldt
Marione Schönfeldt
HGHannah Gunter
Hannah Gunter
HDHalima Dawood
Halima Dawood
KMKerrigan McCarthy
Kerrigan McCarthy
Surveillance systems for monitoring and reporting adverse events following immunisation (AEFI) and adverse events of special interest (AESI) are vital in understanding safety profiles of post-marketed vaccines. Evaluation of surveillance systems is necessary for systems strengthening. We conducted the first evaluation of the South African AEFI surveillance system in its current form, established in 2018. Using CDC guidelines for evaluation of surveillance systems, we conducted a cross-sectional evaluation of system attributes, including quantitative analyses of AEFI/AESI data from 17 May 2021 to 31 December 2022 and qualitative analyses through semi-structured interviews with AEFI surveillance personnel. Findings were used to generate recommendations for system strengthening. The system collects and manages AEFI data, employs investigative tools and has an established AEFI review committee conducting causality assessment, thus meeting WHO minimal capacity for vaccine safety. System adaptation through inclusion of digital applications facilitated public reporting, whilst increasing complexity of database management. Respondents demonstrated engagement with the system through accounts of their roles in AEFI surveillance. Between 17 May 2021 and 31 December 2022, 37,537,009 COVID-19 vaccine doses (BNT162b2 and Ad26.COV2·S) were administered, and 3846 AEFI reported in relation to these vaccines (reporting rate: 10.2/100,000 doses). AEFI reporting rates varied considerably across provinces, ranging from 1.6 to 59.5 AEFI/100,000 doses. In this time period 283 AEFI were reported in relation to non-COVID-19 vaccines. By 31 December 2022, 73.5 % of severe cases that were investigated were causality assessed. We observed a functional, useful, flexible system with high reported stakeholder and public acceptability levels. System challenges included low reporting rates from particular provinces, weak co-ordination between paper and digital reporting and human resource constraints. Recommendations include integration of paper-based and digital surveillance reporting systems to enhance signal detection and eliminate data duplication, provision of dedicated human and financial resources at provincial level and inclusion of active AEFI surveillance through cohort event monitoring.

2 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NNNkosenhle Ndlovu
Nkosenhle Ndlovu
KMKerrigan M. McCarthy
Kerrigan M. McCarthy
VMVictor Vusi Mabasa
Victor Vusi Mabasa
CSChenoa Sankar
Chenoa Sankar
NMNosihle Msomi
Nosihle Msomi
MYMukhlid Yousif
Mukhlid Yousif
Background Sensitive clinical surveillance and high vaccination coverage are required to meet the WHO 2030 measles elimination target. Whilst wastewater and environmental surveillance (WES) has proven usefulness in polio surveillance, it has not been applied to measles control. We describe the development of digital RT-PCR (RT-dPCR) for detection and quantification of measles virus (MeV) in wastewater, and application to retained concentrated samples obtained from 28 national sentinel SARS-CoV-2 wastewater surveillance sites and 19 localised collection points in a single province before, during and after a measles outbreak of over 2,000 laboratory-confirmed cases. Methods We validated a RT-dPCR assay incorporating WHO-recommended primers for detection and differentiation of wild-type and vaccine genotypes. We applied this to retained wastewater samples concentrated by ultrafiltration and stored at −20°C. We compared wastewater findings by district and epidemiological weeks with laboratory-confirmed measles case data obtained from national fever-rash surveillance for districts with adequate surveillance indicators (>2/100,000 non-measles cases) Findings Amongst 2,149 wastewater concentrates obtained between 16 February 2021 and 08 March 2024, we identified 43 (2%) samples containing MeV RNA in concentrations ranging from 2,04-6,11 genome copies/mL. MeV genotype A (vaccine strain) was co-detected in wastewater in 6 instances along with non-A (wild-type) genotypes. Comparison of wastewater and clinical fever-rash surveillance data by epidemiological week and district identified 27 district-time instances where at least one positive wastewater sample was identified, of which 14 (52%) districts reported at least one laboratory-confirmed clinical case in that same epidemiological week. Amongst districts with positive wastewater samples, wastewater surveillance detected MeV in 13/27 (48%) time-district pairs when clinical surveillance failed to detect cases. Amongst district-time instances where at least one laboratory-confirmed measles case was detected (N=127), MeV was detected in at least one wastewater sample collected in that same epidemiological week in 14 (11%) districts Interpretation Wastewater surveillance may be a useful complementary surveillance tool for identification of districts with ongoing measles circulation. MeV detection rates may be improved by real-time testing to limit RNA degradation and improved concentration and nucleic acid extraction processes. Ongoing wastewater surveillance for MeV should be conducted in order to understand the role of WES in measles control and elimination. Funding This work was funded by BMGF (INV-049271)

16 April 2025 in Drug Safety
Verified
Journal Article
Open access
PDF file
CSChenoa Sankar
Chenoa Sankar
SEStephen Evans
Stephen Evans
Johanna Catharina MeyerJohanna Catharina Meyer
Johanna Catharina Meyer
HGHannah May Gunter
Hannah May Gunter
VSVictoria Sekiti
Victoria Sekiti
KMKerrigan McCarthy
Kerrigan McCarthy
Introduction Monitoring of adverse events following immunisation (AEFI) is recommended for post-licensure surveillance. We investigated whether the South African surveillance system could detect signals of disproportionate reporting and whether these signals aligned with globally identified AEFI and adverse events of special interest (AESI) post-coronavirus disease-2019 (COVID-19) vaccination. Methods This retrospective pharmacovigilance study undertook disproportionality analysis of the National Department of Health AEFI database from the start of the COVID-19 vaccine rollout on 17 May 2021 to 31 December 2022. We complemented this with AEFI reports for vaccines not on the routine Expanded Programme on Immunisation schedule, to address potential masking of signals due to the high reporting rate of COVID-19 vaccine AEFI. Results During the study period, 3846 AEFI were reported for 37,537,009 doses of COVID-19 vaccines (BNT162b2 and Ad26.COV2.S) administered. The overall reporting rate was 10.2 per 100,000 doses, 18.1/100,000 and 7.9/100,000 for Ad26.COV2.S and BNT162b2, respectively. Comparison with other countries suggests underreporting. Disproportionate reporting signals were obtained for three and seven AEFI following BNT162b2 and Ad26.COV2.S vaccines, respectively. An additional three AEFI signals from Ad26.COV2.S emerged in the augmented dataset, indicating masking. All Ad26.COV2.S signals, and one BNT162b2 signal, appear in the vaccines’ product information. Among nine AESI evaluated, myocarditis/pericarditis presented as a signal of disproportionate reporting following BNT162b2 vaccination. Conclusions This study is one of the first from a lower-middle-income country, using a spontaneous reporting system for signal detection post-COVID-19 vaccination. Signals aligned with those reported globally. The study highlights the need to further investigate underreporting, masking, and system attributes for system strengthening.

23 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SGSipho Gwala
Sipho Gwala
JLJoshua I. Levy
Joshua I. Levy
VMVictor Vusi Mabasa
Victor Vusi Mabasa
KSKathleen Subramoney
Kathleen Subramoney
NNNkosenhle L. Ndlovu
Nkosenhle L. Ndlovu
MYMukhlid Yousif
Mukhlid Yousif
Measles outbreaks have surged globally in recent years, but current surveillance systems have limited capacity to monitor measles virus (MeV) transmission and evolution at population scale. Although MeV can be detected in wastewater, the public health potential of wastewater genomic surveillance for MeV remains largely unexplored. Here, we deploy sensitive, low-cost MeV wastewater genomic surveillance combining virus concentration, whole-genome amplicon sequencing, and bioinformatic analysis alongside routine clinical genomic surveillance during the 2024-25 outbreak in South Africa. Integrated phylogenetic analyses of wastewater and clinical MeV genomes revealed previously undetected interprovincial spread and transmission links not captured by standard N450 sequencing. Our findings demonstrate that wastewater-integrated whole-genome surveillance expands the coverage and resolution of routine MeV monitoring and provides a scalable tool to advance measles control and elimination efforts.

29 August 2024
Verified
Preprint
Open access
CSChenoa Sankar
Chenoa Sankar
SEStephen Evans
Stephen Evans
HMHannelie Meyer
Hannelie Meyer
GHGunter Hm
Gunter Hm
VSVictoria Sekiti
Victoria Sekiti
KMKerrigan McCarthy
Kerrigan McCarthy
Purpose: Monitoring of adverse events following immunisation (AEFI) is recommended for post-licensure surveillance. We investigated whether the South African surveillance system could detect signals of disproportionate reporting and whether these signals aligned with globally identified AEFI and adverse events of special interest (AESI) post-COVID-19 vaccination. Methods: This retrospective pharmacovigilance study undertook disproportionality analysis of the National Department of Health AEFI database from the start of the COVID-19 vaccine rollout on 17/05/2021 to 31/12/2022. We complemented this with AEFI reports for vaccines not on the routine Expanded Programme on Immunisation schedule, to address potential masking of signals due to the high reporting rate of COVID-19 vaccine AEFI. Results: During the study period, 3846 AEFI were reported for 37,537,009 doses of COVID-19 vaccines (BNT162b2 and Ad26.COV2.S) administered. The overall reporting rate was 10.2 per 100,000 doses, 18.1/100,000 and 7.9/100,000 for BNT162b2 and Ad26.COV2.S, respectively. Comparison with other countries suggests underreporting. Disproportionate reporting signals were obtained for three and seven AEFI following BNT162b2 and Ad26.COV2.S vaccines, respectively. An additional AEFI signal from Ad26.COV2.S emerged in the augmented dataset, indicating masking. All Ad26.COV2.S signals, and one BNT162b2 signal, appear in the vaccines’ product information. Among nine AESI evaluated, myocarditis/pericarditis presented as a signal of disproportionate reporting following BNT162b2 vaccination. Conclusion: This study is one of the first from a lower middle income country, using a spontaneous reporting system for signal detection post-COVID-19 vaccination. Signals aligned with those reported globally. The study highlights needs to further investigate underreporting, masking, and system attributes for system strengthening.